UBS Remains Sidelined on Alkermes plc (ALKS) Following Failed ALKS 5461 Studies

Notable 52-Week Highs and Lows 1/21: (RDCM) High; (ALKS) (MTG) (FITB) Low

52-Week High:Radcom Ltd. (Nasdaq: RDCM) $16.14. Saw a midday surge higher on Thursday. The stock crossed above both the $4 and $5 levels.52-Week Low:Alkermes plc (Nasdaq: ALKS) $33.72.... More

Unusual 11 Mid-Day Movers 1/21: (TROV) (CRC) (UPL) High; (EGL) (ALKS) (BSI) Lower

Trovagene, Inc. (Nasdaq: TROV) 48.4% HIGHER; announced that it has entered into an agreement with America's Choice Provider Network (ACPN) establishing health insurance access to its entire suite of circulating tumor (ct)DNA Precision Cancer Monitoring (PCM) tests and services. Under the terms of the agreement, Trovagene is established as a preferred provider, and its PCM testing services will be covered by over 1,700 payers in North America.

Engility Holdings, Inc. (NYSE: EGL) 44.9% LOWER; issued guidance for fiscal year 2016 and... More

Morgan Stanley Downgrades Alkermes (ALKS) to Underweight

Morgan Stanley downgraded Alkermes (NASDAQ: ALKS) from Overweight to Underweight with a price target of $35.00.

For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.

Shares of Alkermes closed at $60.42 yesterday.

Notable Analyst Rating Changes 1/21: (FIT) (ZFGN) (SPWR) Upgraded; (ERIC) (ALKS) (OIS) Downgraded

UPGRADES
Raymond James upgrades Fitbit (NYSE: FIT) from Market Perform to Outperform with a price target of $25.

RBC Capital boosts Zafgen (Nasdaq:... More

Alkermes (ALKS) PT Cut to $58 at Leerink Partners; Maintains 'Outperform'

Leerink Partners analyst Paul Matteis lowered his price target on Alkermes (NASDAQ: ALKS) to $58.00 (from $84.00) after the company released news on two of its Phase 3 programs for ALKS5461 missing their primary endpoints (PEs). The firm maintained an Outperform rating.

Matteis commented, ". While the... More

Cowen Downgrades Alkermes (ALKS) to Market Perform

Cowen downgraded Alkermes (NASDAQ: ALKS) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.

Shares of Alkermes closed at $60.42 yesterday.

Pre-Open Stock Movers 01/21: (ZFGN) (XLNX) (FEYE) Higher; (OGXI) (ALKS) (SLM) Lower (more...)

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) 41.8% LOWER; announced that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of... More

Alkermes' (ALKS) Two Phase 3 Studies of ALKS 5461 in MDD Failed to Meet Primary Efficacy Endpoint

Alkermes plc (Nasdaq: ALKS) announced preliminary topline results from FORWARD-3 and FORWARD-4, the first two of three phase 3 efficacy studies to read out from the comprehensive FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients who have an... More